Skip to main content
. 2026 Jul 24;18(15):2389. doi: 10.3390/cancers18152389
MM Multiple myeloma
MRD Minimal residual disease
CBC Complete blood count
PAD Bortezomib/adriamycin/dexamethasone
ASCT Autologous stem cell transplantation
NEU Neutrophil count
PLT Platelet count
LMR Lymphocyte monocyte ratio
PFS Progression-free survival
OS Overall survival
ROC Receiver operating characteristic
AUC Area under the curve
FCI Flow cytometric immunophenotyping